VP of Discovery Biology

Are you ready to own the analysis, predictive modeling and interpretation of large-scale perturbation single-cell transcriptomic screens, turning high-dimensional, complex gene expression state changes into clear biological conclusions that drive therapeutic decisions in cardio-renal-metabolic disease?

Large-scale transcriptomic data is at the heart of Gordian’s discovery efforts, and the company will succeed based on our ability to accurately predict physiological changes in disease using single cell gene expression as a readout. In this role, you’ll help ensure our screening and validation decisions are grounded in rigorous, transparent and state-of-the-art analyses, enabling us to confidently prioritize the best targets and interventions.

Gordian Biotechnology is a therapeutics company whose mission is to cure age-related disease and wake up every morning more capable than the day before.

Traditional ex vivo screening methods have failed to produce effective treatments, as age-related diseases have complex causes that include interactions with the aged environment.

To address this problem, Gordian’s Mosaic Screening pools interventions in living animals, producing datasets with causal validation for hundreds of targets, in the living context of disease and mapped to human patients. This data lets us make the most informed choices on what new ideas for treating complex disease, and move validated targets into drug development. (more info on our website, and in our preprint).

We are running this discovery engine in successive indication areas, currently focused on cardiometabolic, to map the in vivo effects of every druggable target across every relevant organ. We then develop drugs and run clinical trials, both internally and in collaboration with multiple partners. And by pooling the data from each program, we can start to identify medicines with broad impact on the multimorbidity and decline caused by aging.

Our mission is audacious, and the path will be full of both challenges and excitement. Two things characterize the Gordian experience:
1) We work as a team, with ownership in our own roles and trust in each other.
2) We strive for extraordinary outcomes, and in doing so grow our skills and capability.

Team – Relying on each other begins with transparency. We set clear goals, visibly connecting individuals and teams to our company objectives. This empowers each of us to make autonomous decisions about our work, knowing how they will affect the bigger picture. Our communication happens out in the open. We give and receive feedback from a perspective of helping each other grow, share mistakes, and ask for help.

Extraordinary – Every day, we ask ourselves, “How could this process or outcome be even better?” Knowing our overall mission, we do what we think will make the most progress, without asking for permission. We don’t shy away from big challenges or unknown territory, we find a way to excel.

Gordian is trying to accomplish something tremendously difficult, and that requires people who care deeply about doing exceptional work. We take ownership of our work, ask every day how we can push our science forward faster, and challenge ourselves, and each other, to continually raise the bar. Holding ourselves and each other to that standard has created an environment where each of us grows into a better version of ourselves.

Doing exceptional work also means building a team that can sustain it. We keep standing meetings to a minimum so people can focus on the science, encourage open collaboration through hands‑on experimentation and “pre‑mortem” discussions that strengthen experimental design, and make time to connect over weekly team lunches. We also encourage people to unplug with an unlimited vacation policy. The combination of mission‑focus, high expectations, and enabling people to thrive has created an environment that talent finds rewarding, as evidenced by a voluntary attrition of only ~6%/yr.

If this environment sounds appealing, help us bring it to life. We are at an exciting inflection point: applying our technology to create comprehensive atlases of therapeutic…